Galanthamine (hydrobromide)

Galanthamine (hydrobromide)

• CAS Number: 1953-04-4
• UNSPSC Description: Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC50 of 0.35 µM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α3β4, α4β2, α6β4 nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD)[1][2][3].
• Target Antigen: Cholinesterase (ChE); nAChR
• Type: Natural Products
• Related Pathways: Membrane Transporter/Ion Channel;Neuronal Signaling
• Applications: Neuroscience-Neurodegeneration
• Field of Research: Neurological Disease
• Assay Protocol: https://www.medchemexpress.com/Galanthamine-hydrobromide.html
• Purity: 99.93
• Solubility: DMSO : 12.5 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : 16.67 mg/mL (ultrasonic;warming;heat to 80°C)
• Smiles: O[C@@H]1C[C@@H]2OC3=C4C(CN(C)CC[C@]42C=C1)=CC=C3OC.Br
• Molecular Weight: 368.27
• References & Citations: [1]L J Scott, et al. Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122.|[2]Marek Samochocki, et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. Pharmacol Exp Ther. 2003 Jun;305(3):1024-36.|[3]Acharya Balkrishna, et al. Anti-Acetylcholinesterase Activities of Mono-Herbal Extracts and Exhibited Synergistic Effects of the Phytoconstituents: A Biochemical and Computational Study. Molecules. 2019 Nov; 24(22): 4175.|[4]Balpreet Matharu, et al. Galantamine inhibits beta-amyloid aggregation and cytotoxicity. J Neurol Sci. 2009 May 15;280(1-2):49-58.|[5]Debby Van Dam, et al. Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology (Berl). 2005 Jun;180(1):177-90.|[6]Johan Monbaliu, et al. Pharmacokinetics of galantamine, a cholinesterase inhibitor, in several animal species. Arzneimittelforschung. 2003;53(7):486-95.Acta Pharmacol Sin. 2024 Mar 4.|Antioxidants (Basel). 2022, 11(7), 1228.|Free Radic Biol Med. 2019 Dec;145:20-32.|Heliyon. 2024 Jun 03.|Antioxidants (Basel). 2022 Feb 14;11(2):385.|Asian Pac J Trop Med. 2018, 8(10):500-512.|Biochem Pharmacol. 2020 Oct;180:114139.|bioRxiv. 2023 Jun 3.|J Chromatogr A. 2023 Aug 25, 464330.|J Pharmacol Sci. 21 February 2022.|Microorganisms. 2022, 10(10), 2089.|Nat Commun. 2023 Apr 17;14(1):2182.|PLoS Biol. 2024 June 27.|Research Square Preprint. June 16th, 2022.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
• Clinical Information: Launched